Roopal Thakkar, M.D.: key facts
- Kind of voice
- Academic
- Role
- Chief Scientific Officer and EVP of R&D at AbbVie
- Quoted on
- Cosmetic procedures & aesthetics
- Press citations held
- 1
- Most recently quoted
- 29 Sept 2026
“We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics. Though disappointed, we remain confident in the strength and integrity of our application, and we are well-positioned to respond to the agency's feedback promptly to support completion of the review.”
Where Roopal Thakkar, M.D. has been quoted
- FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLsfiercepharma.com · 29 Sept 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.